Processa Pharmaceuticals Files 8-K with Corporate Updates

TL;DR

Processa Pharma filed an 8-K on April 3rd, updating corporate info and financials. No major news, just housekeeping.

AI Summary

Processa Pharmaceuticals, Inc. filed an 8-K on April 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits as of April 3, 2024. The filing details the company's principal executive offices in Hanover, Maryland, and its former name, Heatwurx, Inc., which was changed on October 28, 2011.

Why It Matters

This 8-K filing provides essential corporate information and disclosures, which are important for investors to stay informed about the company's status and any regulatory compliance.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for corporate information and does not appear to contain significant new risks or material adverse events.

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — Registrant
• Heatwurx, Inc. (company) — Former Company Name
• April 3, 2024 (date) — Date of earliest event reported
• April 4, 2024 (date) — Filing Date
• Hanover, Maryland (location) — Principal Executive Offices

FAQ

Filing Documents

• form8-k.htm (8-K) — 40KB
• ex99-1.htm (EX-99.1) — 14KB
• ex99-1_001.jpg (GRAPHIC) — 244KB
• ex99-1_002.jpg (GRAPHIC) — 530KB
• ex99-1_003.jpg (GRAPHIC) — 318KB
• ex99-1_004.jpg (GRAPHIC) — 287KB
• ex99-1_005.jpg (GRAPHIC) — 295KB
• ex99-1_006.jpg (GRAPHIC) — 239KB
• ex99-1_007.jpg (GRAPHIC) — 292KB
• ex99-1_008.jpg (GRAPHIC) — 255KB
• ex99-1_009.jpg (GRAPHIC) — 350KB
• ex99-1_010.jpg (GRAPHIC) — 263KB
• ex99-1_011.jpg (GRAPHIC) — 227KB
• ex99-1_012.jpg (GRAPHIC) — 320KB
• ex99-1_013.jpg (GRAPHIC) — 316KB
• ex99-1_014.jpg (GRAPHIC) — 231KB
• ex99-1_015.jpg (GRAPHIC) — 352KB
• ex99-1_016.jpg (GRAPHIC) — 576KB
• 0001493152-24-013132.txt ( ) — 7244KB
• pcsa-20240403.xsd (EX-101.SCH) — 3KB
• pcsa-20240403_lab.xml (EX-101.LAB) — 33KB
• pcsa-20240403_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 3, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 7380 Coca Cola Drive , Suite 106 , Hanover , Maryland 21076 (Address of Principal Executive Offices, Including Zip Code) (443) 776-3133 (Registrant's Telephone Number, Including Area Code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock: Par value $.0001 PCSA Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01. Regulation Disclosure. George Ng, CEO for Processa Pharmaceuticals, Inc. (" Processa ") presented at the MedInvest Biotech + Pharma Investor Conference held on April 3, 2024 in New York City. Mr. Ng's presentation titled "Next Generation Chemotherapy: Improved Treatment for More Patients" was held on April 3, 2024 at 10:55 AM ET. Dr. David Young, President R&D attended the meeting virtually. During the session, Processa's presentation was uploaded into a portal, which is furnished as Exhibit 99.1 and is incorporated herein by reference. The presentation will also be made available in the "Investors" section on Processa's website, located at https://www.processapharmaceuticals.com. Processa undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases, or through other public disclosure, including in the "Investors" section of Processa's website. Processa routinely uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Processa Pharmaceuticals Presentation dated April 3, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on April 4, 2024. PROCESSA PHARMACEUTICALS, INC. Registrant By: /s/ George Ng George Ng Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR